In the rapidly evolving field of biotechnology, the development and approval of innovative therapeutic drugs represent a significant milestone. On July 16, Huiyu Pharmaceutical announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (Huiyu Haiyue), had received the “Notice of Acceptance” from the State Drug Administration for the clinical trial application of HY07121 for injection (project R&D code “HY-0007”).

This drug, designed for the treatment of advanced solid tumors, represents a major step forward in cancer therapy. Central to the successful progression of this project was the utilization of Hzymes Biotech’s N-Glycan Kit, which played a critical role in the drug’s development and subsequent approval for clinical trials.

Background on HY-0007

HY-0007 is an innovative therapeutic biological product developed by Huiyu Haiyue. It is an anti-PD-1, anti-TIGIT, IL-15/IL-15Rα bispecific antibody fusion protein, registered as a Class 1 innovative therapeutic biological product. This designation indicates that it is a novel therapeutic biological product that has not been marketed domestically or internationally.

Preclinical Studies

The preclinical studies of HY-0007 demonstrated its potential to significantly enhance immune responses against tumors. The in vitro pharmacodynamic studies indicated that HY-0007 could stimulate the secretion level of human immune cytokine IFN-γ more effectively than the combined effect of the three targets it is designed to address. Furthermore, in vivo studies showed that HY-0007 maintained efficacy against PD-1 antibody-resistant tumor models, indicating its potential to overcome existing therapeutic challenges in cancer treatment.

Mechanism of Action

The mechanism of action of HY-0007 involves two primary pathways:

1.Replenishment of Immune Cells: HY-0007 increases the number of intratumoral effector cells, which are crucial for an effective immune response.
2.Restoration of Immune Cell Function: It restores the function of immune cells that have been depleted due to continuous engagement in fighting the tumor, enhancing immune efficacy and overcoming acquired drug resistance in some patients.

These mechanisms highlight HY-0007’s potential to provide a new treatment option for patients with advanced tumors, combining the enhancement of tumor immunotherapy efficacy with the ability to overcome immune resistance.

The Role of Hzymes Biotech’s N-Glycan Kit

Glycosylation, the process by which sugars are chemically attached to proteins, plays a critical role in the stability, efficacy, and safety of therapeutic antibodies. The characterization of glycan structures is essential for the development of biopharmaceuticals. Hzymes Biotech’s N-Glycan Kit was instrumental in the development of HY-0007, providing a reliable and efficient method for glycan analysis.

Importance of Glycan Analysis in Biopharmaceutical Development

Glycan structures can affect the pharmacokinetics and pharmacodynamics of therapeutic antibodies. Proper glycosylation is necessary to ensure that the antibody functions correctly, remains stable, and does not elicit an unwanted immune response. The N-Glycan Kit from Hzymes Biotech facilitated comprehensive glycan analysis, ensuring that HY-0007 met the necessary quality standards for clinical application.

Application of the N-Glycan Kit in HY-0007 Development

The N-Glycan Kit enabled Huiyu Haiyue to perform detailed glycan profiling of HY-0007. This profiling was critical in several stages of development:

– Quality Control: 

Ensuring consistency in glycosylation patterns across different batches of HY-0007.

– Efficacy Testing: 

Analyzing the impact of glycan structures on the efficacy of the antibody.

– Safety Assessment: 

Identifying any glycan-related issues that could lead to adverse immune reactions.

Through these applications, the N-Glycan Kit provided Huiyu Haiyue with the data necessary to refine and validate HY-0007, contributing significantly to the successful acceptance of the clinical trial application.

Clinical Trial Application and Approval

The acceptance of the clinical trial application for HY-0007 marks a significant achievement for Huiyu Pharmaceutical. This success can be attributed to the thorough preclinical studies and the meticulous glycan analysis facilitated by Hzymes Biotech’s N-Glycan Kit.

Detailed Overview of the Clinical Trial Application

The clinical trial application process involves several critical steps, including:

1.Preclinical Data Submission: 

Comprehensive data from in vitro and in vivo studies, demonstrating the safety and efficacy of HY-0007.

2.Quality Control Documentation: 

Detailed reports on the manufacturing process, including glycan analysis results.

3.Clinical Trial Design: 

A well-structured plan for the clinical trial, outlining the objectives, methodologies, and endpoints.

The acceptance of HY-0007 for clinical trials signifies that the State Drug Administration recognized the robustness of the preclinical data and the quality of the drug, much of which was assured through the glycan profiling provided by the N-Glycan Kit

Hzymes Biotech N-Glycan Kit

Product feature:

• Easy to operate and fast labeling
• Pre analysis processing can be completed within 30 minutes
• High fluorescence and mass spectrometry sensitivity
• Accurate molecular weight labeling
• Less losses.The minimum sample usage is as low as 15 μg
• Available in two versions: SPE column and 96 well plate

• High cost-effectiveness
• Product formation

Design

Operation process

Spectrum of labeled molecular weight.

Products

Product Name	Catalog No.	Packing Specifications
N-Glycan Kit (96 well plate)	HBP003101	24T
N-Glycan Kit (96 well plate)	HBP003102	96T
N-Glycan Kit (SPE column)	HBP003103	24T

Conclusion

The acceptance of the clinical trial application for HY-0007 is a testament to the innovative capabilities of Huiyu Pharmaceutical and the vital role played by Hzymes Biotech’s N-Glycan Kit. This case study highlights the importance of comprehensive glycan analysis in the development of therapeutic antibodies and the potential impact of HY-0007 on the treatment of advanced solid tumors. As the clinical trials progress, the biopharmaceutical industry will be closely watching the outcomes, hopeful that HY-0007 will become a new beacon of hope for cancer patients worldwide.

In the future, Hzymes biotech will always remember its original intention and persist in meticulous cultivation in the IVD field. It will adhere to independent research and development, accelerate the construction of a world-class specialty enzyme production platform, and achieve import substitution of core enzyme raw materials in the field of biomedicine in China. It will collaborate with leading biopharmaceutical companies to expand their global presence and contribute to the advancement of the industry.